Amarin Corporation plc
Amarin Corporation plc is a biopharmaceutical company focused on cardiovascular health, centered on the commercialization and development of VASCEPA (icosapent ethyl). The company is incorporated in England and Wales, with principal offices in Dublin and a primary U.S. office in New Jersey, and it operates as a single business segment.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueDirect and partner-based sales of 1-gram and 0.5-gram VASCEPA capsules.
Upfront, milestone, sales-based, and royalty income from ex-U.S. agreements.
Products
Reported · share of revenue- Products85.5 %
- Licensing and Royalty14.5 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Amarin sells primarily into the pharmaceutical distribution channel, with U.S. sales going to major wholesalers, regional wholesalers, mail-order pharmacy providers, and select retail pharmacy chains. Outside the U.S., customers are commercial partners and wholesalers that resell VASCEPA within their licensed territories. The end demand ultimately comes from patients using VASCEPA by prescription for cardiovascular risk management.
Buy VASCEPA in bulk and resell it through retail pharmacy channels; they are the core route to market in the U.S.
Purchase through wholesale channels to dispense VASCEPA to patients under prescription.
License and distribution partners that buy VASCEPA for resale and promotion in their territories.
Select chains that buy directly for patient dispensing in the U.S. market.
Physicians prescribe VASCEPA and patients use it for triglyceride reduction and CV risk reduction.
Strategy
Amarin’s strategy centers on defending and extending VASCEPA’s commercial footprint while using partnerships to expand outside the U.S. The company also emphasizes lifecycle management and development of derivative or next-generation cardiovascular products to reduce dependence on a single asset. Supply-chain alignment and inventory management are important operational priorities because the business relies on third-party manufacturers and a concentrated distribution model.
The company is highly dependent on one branded product, so maintaining access and prescription volume is central to revenue.
Ex-U.S. markets diversify revenue and can extend the product life cycle through local partners.
New or derivative products could reduce single-product dependence and support longer-term growth.
Third-party manufacturing and purchase commitments require careful matching of supply to demand.
Geography
Amarin’s commercial base is the United States, where most product revenue is generated through VASCEPA sales. The company also sells in certain European countries and in other non-U.S. markets through collaborations with third-party partners, which broadens geographic reach but also changes the revenue mix toward partner-based economics. Its operating footprint spans Ireland, England, and the U.S., reflecting a cross-border corporate and commercial structure.
Risks
Amarin is highly dependent on VASCEPA, so any loss of market access, pricing pressure, or competitive displacement can materially affect the business. The company also faces concentration risk in its customer base, reliance on third-party manufacturers and partners, and the regulatory and clinical uncertainty typical of pharmaceutical development. Cybersecurity, intellectual property, and accounting estimates around revenue, inventory, and taxes are additional areas investors should monitor.
Most revenue is tied to VASCEPA, so any commercial setback has an outsized effect.
Exposure: VASCEPA commercialization in the U.S. and abroad
Approved generic versions can reduce pricing and volume in the U.S. market.
Exposure: U.S. branded prescription market
A small number of wholesalers account for a large share of sales and receivables.
Exposure: U.S. distributor channel
Manufacturing and supply rely on external parties and minimum purchase commitments.
Exposure: API and finished-dose supply chain
Sensitive patient, vendor, and company data could be disrupted or exposed.
Exposure: Internal systems and vendor networks
Accounting
Judgemental itemsU.S. sales are recognized on delivery, while partner sales depend on control transfer.
Impact: Quarterly revenue can shift with shipment timing and partner activity.
Rebates, chargebacks, discounts, and returns reduce gross product revenue.
Impact: Net sales depend on estimates of future deductions.
The company holds significant inventory, including inventory approved for North America.
Impact: Write-downs or obsolescence could affect cost of sales and assets.
Loss history affects whether tax benefits are realizable.
Impact: Tax expense and balance sheet tax assets depend on management judgment.
Similar listed companies
Publicly listed companies with a comparable business focus.
NewAmsterdam Pharma Co N.V.
NAMS · Pharmaceutical Preparations
IRLAB Therapeutics
IRLAB-A · Health Care
IRLAB Therapeutics is a Swedish biopharmaceutical company focused on discovering and developing novel treatments for Parkinson's disease and other central nervous system (CNS) disorders.
ArriVent BioPharma, Inc.
AVBP · Pharmaceutical Preparations
Galmed Pharmaceuticals Ltd.
EOCN · Pharmaceutical Preparations
AstraZeneca PLC
AZN · Pharmaceutical Preparations
AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines.
Alkermes plc.
ALKS · Pharmaceutical Preparations
Alkermes plc is a biopharmaceutical company focused on neuroscience, with commercial medicines for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy.
Last updated: 11/08/2026